Host RNA Expression Profiles and Protein Biomarkers in Neonatal Herpes Simplex Virus Infection

Neonatal Sepsis Clinical Trial

Official title:

Host RNA Expression Profiles and Protein Biomarkers in Neonatal Herpes Simplex Virus Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05226949
• Other study ID #: H-21009288-HSV
• Status: Completed
• Start date: January 1, 2022
• Est. completion date: April 30, 2022

Study information

• Verified date: December 2022
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study seeks to identify and test host RNA expression profiles in context to protein biomarkers in dried blood spot samples as novel diagnostic markers of neonatal herpes simplex virus infection and to improve the understanding of the pathogenesis of the disease.

Description:

Background: Herpes Simplex Virus (HSV) infection in newborns is uncommon but can be devastating and is associated with significant morbidity and mortality. The diagnosis of neonatal HSV infection is challenging because maternal genital herpes often is asymptomatic and the clinical presentation in newborns can be nonspecific, especially in the early disease stages. This results in late diagnosis and potentially terrible consequences for the newborn. The reason why some newborns develop severe disease due to HSV infection is unknown. It has been suggested that immunologic differences in early infancy are the key to further advances. Host RNA expression profiling, transcriptomics, of the host response to infections has shown great potential as clinical tool for diagnostics and for unveiling molecular disease mechanisms. As previously shown, reliable host RNA expression data can be obtained from neonatal dried blood spot (DBS) samples by RNA-sequencing. Proteomic analysis has the potential to simultaneously identify hundreds of protein biomarkers and immune cell populations allowing for detailed mapping of disease immunological pathways. Method: A nationwide retrospective case-control study of all newborns with HSV infection in Denmark from 2010 through 2019. DBS samples will be obtained from the Danish Neonatal Screening Biobank, Statens Serum Institut. RNA sequencing and proteomic analyses will be performed at the Danish Center for Neonatal Screening, Department of Congenital Disorders, Statens Serum Institut. Cases will be randomly assigned to a "Discovery cohort" and compared to a control group of newborns matched on gestational age, sex and birthweight will be included. Time frame: Sample identification/recruiting: January 1st to January 31st 2022. Sample analysis (RNA sequencing and proteomic analysis): February 1st to April 30th 2022. Perspectives: New molecular-based diagnostic tools complementary to conventional methods may improve early diagnosis of neonatal HSV infections and lead to optimised management. In addition, understanding of the pathogenesis at a molecular level of severe disease manifestations of the disease, could form the basis for development of novel interventions for better prevention and treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 159
• Est. completion date: April 30, 2022
• Est. primary completion date: February 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 0 Days to 28 Days

Eligibility

Inclusion Criteria:

1. cases of newborns aged 0-28 days with verified HSV infection (positive HSV PCR in blood, cerebrospinal fluid and/or swab sample)

2. controls of newborns without infection matched on gestational age, sex and birthweight

Exclusion Criteria:

1. dried blood spot samples that are not allowed to be used for research

2. dried blood spots samples containing insufficient amount of blood for research

Related Conditions & MeSH terms

• Communicable Diseases
• Herpes Simplex
• Herpes Simplex Virus Infection
• Infections
• Neonatal Death
• Neonatal Herpes Simplex Infection
• Neonatal Infection
• Neonatal Sepsis
• Newborn; Infection
• Perinatal Death
• Pregnancy Complications, Infectious
• Viral Infection
• Virus Diseases

Locations

Country	Name	City	State
Denmark	Department of Congenital Disorders, Statens Serum Institut	Copenhagen
Denmark	Department of Paediatrics and Adolescent Medicine, Rigshospitalet	Copenhagen

Sponsors (2)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark	Statens Serum Institut

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Host RNA expression and proteomic profiles	To identify specific host RNA expression and proteomic profiles in dried blood spot samples from newborns with HSV infection	Admission, age 0-28 days
Secondary	Disease pathogenesis	Mapping of disease immunological pathways by simultaneous host RNA expression profiling and proteomic analysis	Admission, age 0-28 days
Secondary	Application of known host RNA profiles	To test host RNA profiles published in other studies, e.g. based on the genes IFI44L and FAM89A	Admission, age 0-28 days